Buparlisib (BKM120) is a potent, selective, ATP-competitive pan-PI3K inhibitor. It affects the PI3K/AKT/mTOR signaling pathway by downregulating AKT phosphorylation, effectively inhibiting tumor cell proliferation and inducing apoptosis.
Buparlisib (BKM120) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Buparlisib (BKM120) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.